These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

329 related items for PubMed ID: 16024640

  • 21. Photodynamic efficiency of macrophage activity using a photosensitizer, lumin, with near-IR laser light for photoimmunotherapy of a cancer.
    Mito K.
    Front Med Biol Eng; 1996; 7(2):81-92. PubMed ID: 8803558
    [Abstract] [Full Text] [Related]

  • 22. SV40 T/t-common polypeptide specifically induces apoptosis in human cancer cells that overexpress HER2/neu.
    Wen CC, Cheng SA, Hsuen SP, Huang YL, Kuo ZK, Lee HF, Kuo CH, Du JL, Wang WB.
    Cancer Res; 2006 Jun 01; 66(11):5847-57. PubMed ID: 16740724
    [Abstract] [Full Text] [Related]

  • 23. Photodynamic cell-kill analysis of breast tumor cells with a tamoxifen-pyropheophorbide conjugate.
    Fernandez Gacio A, Fernandez-Marcos C, Swamy N, Dunn D, Ray R.
    J Cell Biochem; 2006 Oct 15; 99(3):665-70. PubMed ID: 16795032
    [Abstract] [Full Text] [Related]

  • 24. Combination photoimmunotherapy with monoclonal antibodies recognizing different epitopes of human epidermal growth factor receptor 2: an assessment of phototherapeutic effect based on fluorescence molecular imaging.
    Ito K, Mitsunaga M, Nishimura T, Kobayashi H, Tajiri H.
    Oncotarget; 2016 Mar 22; 7(12):14143-52. PubMed ID: 26909859
    [Abstract] [Full Text] [Related]

  • 25. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial.
    Mittendorf EA, Storrer CE, Foley RJ, Harris K, Jama Y, Shriver CD, Ponniah S, Peoples GE.
    Cancer; 2006 Jun 01; 106(11):2309-17. PubMed ID: 16596621
    [Abstract] [Full Text] [Related]

  • 26. Photochemical activation of the recombinant HER2-targeted fusion toxin MH3-B1/rGel; Impact of HER2 expression on treatment outcome.
    Bull-Hansen B, Cao Y, Berg K, Skarpen E, Rosenblum MG, Weyergang A.
    J Control Release; 2014 May 28; 182():58-66. PubMed ID: 24637464
    [Abstract] [Full Text] [Related]

  • 27. Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response.
    Stagg J, Sharkey J, Pommey S, Young R, Takeda K, Yagita H, Johnstone RW, Smyth MJ.
    Proc Natl Acad Sci U S A; 2008 Oct 21; 105(42):16254-9. PubMed ID: 18838682
    [Abstract] [Full Text] [Related]

  • 28. Multimodality agents for tumor imaging (PET, fluorescence) and photodynamic therapy. A possible "see and treat" approach.
    Pandey SK, Gryshuk AL, Sajjad M, Zheng X, Chen Y, Abouzeid MM, Morgan J, Charamisinau I, Nabi HA, Oseroff A, Pandey RK.
    J Med Chem; 2005 Oct 06; 48(20):6286-95. PubMed ID: 16190755
    [Abstract] [Full Text] [Related]

  • 29. Viral transduction of the HER2-extracellular domain expands trastuzumab-based photoimmunotherapy for HER2-negative breast cancer cells.
    Shimoyama K, Kagawa S, Ishida M, Watanabe S, Noma K, Takehara K, Tazawa H, Hashimoto Y, Tanabe S, Matsuoka J, Kobayashi H, Fujiwara T.
    Breast Cancer Res Treat; 2015 Feb 06; 149(3):597-605. PubMed ID: 25616354
    [Abstract] [Full Text] [Related]

  • 30. Potent and specific antitumor effect of CEA-targeted photoimmunotherapy.
    Shirasu N, Yamada H, Shibaguchi H, Kuroki M, Kuroki M.
    Int J Cancer; 2014 Dec 01; 135(11):2697-710. PubMed ID: 24740257
    [Abstract] [Full Text] [Related]

  • 31. Near-Infrared Photoimmunotherapy Using a Small Protein Mimetic for HER2-Overexpressing Breast Cancer.
    Yamaguchi H, Pantarat N, Suzuki T, Evdokiou A.
    Int J Mol Sci; 2019 Nov 20; 20(23):. PubMed ID: 31757056
    [Abstract] [Full Text] [Related]

  • 32. Affibody-displaying bionanocapsules for specific drug delivery to HER2-expressing cancer cells.
    Shishido T, Mieda H, Hwang SY, Nishimura Y, Tanaka T, Ogino C, Fukuda H, Kondo A.
    Bioorg Med Chem Lett; 2010 Oct 01; 20(19):5726-31. PubMed ID: 20801029
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Control of breast tumor cell growth using a targeted cysteine protease inhibitor.
    Xing R, Wu F, Mason RW.
    Cancer Res; 1998 Mar 01; 58(5):904-9. PubMed ID: 9500448
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Antibody Targeted Photolysis.
    Yarmush ML, Thorpe WP, Strong L, Rakestraw SL, Toner M, Tompkins RG.
    Crit Rev Ther Drug Carrier Syst; 1993 Mar 01; 10(3):197-252. PubMed ID: 8258158
    [Abstract] [Full Text] [Related]

  • 38. Targeting HER2+ breast cancer cells: lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles.
    Owen SC, Patel N, Logie J, Pan G, Persson H, Moffat J, Sidhu SS, Shoichet MS.
    J Control Release; 2013 Dec 10; 172(2):395-404. PubMed ID: 23880472
    [Abstract] [Full Text] [Related]

  • 39. Photoimmunotherapy and biodistribution with an OC125-chlorin immunoconjugate in an in vivo murine ovarian cancer model.
    Goff BA, Hermanto U, Rumbaugh J, Blake J, Bamberg M, Hasan T.
    Br J Cancer; 1994 Sep 10; 70(3):474-80. PubMed ID: 8080733
    [Abstract] [Full Text] [Related]

  • 40. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation.
    Grabert RC, Cousens LP, Smith JA, Olson S, Gall J, Young WB, Davol PA, Lum LG.
    Clin Cancer Res; 2006 Jan 15; 12(2):569-76. PubMed ID: 16428502
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.